FDA still skeptical of ALS drug ahead of high-stakes meeting

Federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease, even as they prepare to give its drugmaker a rare second opportunity to make a public case for the treatment.

Source: washingtontimes.com

Please follow and like us: